{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Atopic&page=29", "query": { "condition": "Atopic", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 712, "total_pages": 72, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Atopic&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Atopic&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T23:50:07.721Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05387707", "title": "Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pruritus", "Atopic Dermatitis" ], "interventions": [ { "name": "difelikefalin 0.25 mg", "type": "DRUG" }, { "name": "difelikefalin 0.5 mg", "type": "DRUG" }, { "name": "TCS Cream", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cara Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 287, "start_date": "2022-08-16", "completion_date": "2024-02-02", "has_results": false, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-10-30T23:50:07.721Z", "location_count": 61, "location_summary": "Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05387707" }, { "nct_id": "NCT03531957", "title": "Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "ASN002", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asana BioSciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 244, "start_date": "2018-07-05", "completion_date": "2019-08-14", "has_results": true, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-10-30T23:50:07.721Z", "location_count": 30, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Fremont, California + 24 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03531957" }, { "nct_id": "NCT07298395", "title": "Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis (AD)" ], "interventions": [ { "name": "ENV-294", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enveda Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 105, "start_date": "2025-12-22", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-30T23:50:07.721Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07298395" }, { "nct_id": "NCT03703102", "title": "Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "KHK4083", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 274, "start_date": "2018-10-22", "completion_date": "2020-11-12", "has_results": true, "last_update_posted_date": "2024-04-26", "last_synced_at": "2026-10-30T23:50:07.721Z", "location_count": 13, "location_summary": "Huntington Beach, California • Irvine, California • Los Angeles, California + 10 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03703102" }, { "nct_id": "NCT04927572", "title": "Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "FMX114", "type": "DRUG" }, { "name": "Vehicle", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vyne Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-10-13", "completion_date": "2022-08-09", "has_results": false, "last_update_posted_date": "2022-08-31", "last_synced_at": "2026-10-30T23:50:07.721Z", "location_count": 4, "location_summary": "Miami, Florida • Miramar, Florida • Sugarloaf, Pennsylvania", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miramar", "state": "Florida" }, { "city": "Sugarloaf", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04927572" }, { "nct_id": "NCT04693195", "title": "A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Pruritus", "Atopic Dermatitis" ], "interventions": [ { "name": "BLU-5937", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bellus Health Inc. - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 142, "start_date": "2020-12-09", "completion_date": "2021-10-12", "has_results": false, "last_update_posted_date": "2022-10-17", "last_synced_at": "2026-10-30T23:50:07.721Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04693195" }, { "nct_id": "NCT04392154", "title": "Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Lebrikizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1153, "start_date": "2020-06-15", "completion_date": "2025-04-22", "has_results": true, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-10-30T23:50:07.721Z", "location_count": 160, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04392154" }, { "nct_id": "NCT07560618", "title": "Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "ITCH", "Atopic Dermatitis" ], "interventions": [ { "name": "Roflumilast Cream 0.15%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Integrative Skin Science and Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 40, "start_date": "2026-07-21", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-30T23:50:07.721Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07560618" }, { "nct_id": "NCT05155085", "title": "A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "AK002", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Allakos Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 131, "start_date": "2022-06-27", "completion_date": "2024-04-17", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-10-30T23:50:07.721Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05155085" }, { "nct_id": "NCT06524635", "title": "A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa", "Atopic Dermatitis" ], "interventions": [ { "name": "Lutikizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2024-08-14", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2025-01-24", "last_synced_at": "2026-10-30T23:50:07.721Z", "location_count": 2, "location_summary": "Sacramento, California • Ann Arbor, Michigan", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06524635" } ] }